Lex­eo brings in $95M; FDA lifts hold on Nurix can­cer tri­al

Plus, news about Ven­tyx Bio­sciences, CEPI, Evo­lus, Re­cur­sion and Sen­so­ri­on:

Lex­eo Ther­a­peu­tics rais­es $95M: The fi­nanc­ing is near­ly the same size as the gene ther­a­py mak­er’s $100 mil­lion IPO four months ago. The new mon­ey from No­vo Hold­ings and oth­er in­vestors is ex­pect­ed to give the clin­i­cal-stage biotech run­way in­to 2027. — Kyle LaHu­cik

Nurix Ther­a­peu­tics gets FDA go-ahead to con­tin­ue tri­al: The reg­u­la­tor lift­ed its par­tial hold on Nurix’s Phase Ia/Ib clin­i­cal tri­al in­ves­ti­gat­ing NX-2127 to treat B-cell ma­lig­nan­cies. The FDA halt­ed the tri­al in No­vem­ber af­ter the com­pa­ny said it want­ed to change the man­u­fac­tur­ing process for the drug. NX-2127 works by de­grad­ing ​​BTK and IMiD neo­sub­strates. — An­na Brown

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER